HUE025134T2 - A humán granulocita makrofág kolóniastimuláló faktor ellenanyag neutralizálói - Google Patents
A humán granulocita makrofág kolóniastimuláló faktor ellenanyag neutralizálói Download PDFInfo
- Publication number
- HUE025134T2 HUE025134T2 HUE06724392A HUE06724392A HUE025134T2 HU E025134 T2 HUE025134 T2 HU E025134T2 HU E06724392 A HUE06724392 A HU E06724392A HU E06724392 A HUE06724392 A HU E06724392A HU E025134 T2 HUE025134 T2 HU E025134T2
- Authority
- HU
- Hungary
- Prior art keywords
- ser
- val
- leu
- thr
- pro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
Claims (9)
1. Humán monoklonális ellenanyag, vagy annak fragniense, amely a következő komponenseket tartalmazza a. egy könnyű lánc variábilis régié, amely tartalmaz egy, a 19. számú szekvencía-vázlaton immutatött aminosav szekvenciái, valamint tartalmaz egy nehéz Une variábilis régiét, amelyet a következők közül választhatunk ki: i. a 21. számi szekvencia-vázlaton bemutatott szekvenciával rendelkező am inosav szekvencia; ii. a 22. számú szekvenda-vázlaton bemutatott szekvenciával rendelkező aminosav szekvencia; íü, az 52. számú szekvencia-vázlaton bemutatott szekvenciával rendelkező aminosav szekvencia; és Ív. az 53. számú szekvencia-vázlaton bemutatott szekvenciával rendelkező aminosav szekvencia; vagy b. egy könnyű lánc variábilis régié, amely tartalmaz egy, az 54, számú szekvencia-vázlaton bemuÄtt aminosay SZékvendit, valamint tartaimaz egy nehéz lánc variábilis régiót, amoiyet á következők közűt viiaazthatunk ki: t. a 23. számú szekvencia-vázlaton bemutatott szekvenciával rendelkező aminosav szekvencia; sí, a 26. számú szekvencia-vázlaton bemutatott szekvenciával rendelkező amínesav szekvencia; ás íii. a 28. számú szekvencia-vázlaton bemutatót szekvenciával rendelkező aminosav szekvenda; vagy c. egy könnyű lánc variábilis régió, amely tartalmaz egy, az 55. számú szekvencia-vázlaton bemutatott aminosav szekvenciát, valamint tartalmaz egy nehéz lánc variábilis régiót, amelyet a kővetkezők közöl választhatunk ki: i, a 21. számú szekvencia-vázlaton bemutatott szekvenciával rendelkező aminosav szekvencia; és Ii, a 22, számú szekvencia-vázlaton bemutatott szekvenciával rendelkező aminosav szekvencia; vagy d. egy könnyű lánc variábilis régié, amely tartalmaz egy, a 34. szárai szekvencia-vázlaton bemutatott aminosav szekvenciát, valamint tartalmaz egy nehéz lánc va-riábls régiót, amelyet a következők közül választhatunk ki; i a 35. számú szekvencia-vázlaton bemutatott szekvenciával rendelkező ammosav szekvencia; il a 37. számú szekvencia-vázlaton bemutatott szekvenciával rendelkező ammosav szekvencia; 1, a 40. számú szekvencia-vázlaton bemutatott szekvenciával rendelkező ammosav szekvencia; iv, a 42. számú szekvencia-vázlaton bemutatott szekvenciával rendelkező aminosav szekvencia; és V. a 48. számú szekvencia-vázlaton bemutatott szekvenciává! rendelkező aminosav szekvencia
2. Az 1. igénypont szerinti dumán monokionáiís ellenanyag, vagy annak fragmense, amely tartalmaz egy könnyű lánc variábilis régiét, amely tartalmaz egy, a 19. számú szekvenciával rendelkező aminosav szekvenciát, valamint tartalmaz égy nehéz lánc variábilis régiót, amelyet a 21. és számú szekvenciával rendelkező aminosav szekvenciák közöl választunk ki.
3. Az 1, igénypont szerinti humán monokionáiís ellenanyag, vagy annak fragmense, amely tartalmaz egy 'könnyű lánc variábilis régiét, amely tartalmaz egy, a 34. számú szekvenciával rendelkező aminosav szekvenciát, valamint tartalmaz egy nehéz lánc variábilis régiót, amely a 35. számé szekvenciával rendelkező nehéz lánc variábilis régiót tartalmaz.
4. Az 1-3, igénypontok bármelyike szerinti humán monokionáiís ellenanyag fragmense, amely sz#art forgó fragmens egy scFv, egy Fv, egy diabody, egy tandem diabody, egy Fab, egy Fafy vágy egy F(ab}2.
5. Polinukíeotid moíekula, amely az 1-3. igénypontok bármelyike szerinti monokionáiís ellenanyagot vagy annak fragmensét kódolja.
6. Gyógyászati készítmény, amely az 1 -4. igénypontok bármelyike szerinti humán mono-kíonáiis ellenanyagot vagy annak fragmensét tartalmazza, vagy egy, az 5, igénypont szerinti polinukíeotid molekulát.
7. Az 1 -4. igénypontok bármelyike szerinti humán monokionáiís ellenanyag vagy annak fragmense, vagy az 3. igénypont szerinti poílnukteotld molekula, amely adott esetben tartalmaz egy vagy több további gyuiladáselienes szert, gyulladásos betegségek kezelési módszereiben történő alkalmazásra.
I. Humán monokionáiís ellenanyag, vagy annak fragmense, vagy a polinukíeotid molekula 7, igénypont szerinti alkalmazása, ahol a szóban forgó gyulladásos betegségeket a következő csoportból választjuk ki: reumás arthritis (RA) (beleértve az olyan RA~t, amely rezísztens a TNF-aifa neutmfizálökkat való kezelésre), asztma, szkíerózis multiplex (MS), krónikus obstruktiv tüdőbetegség (CÖPD), akut légzési nehézség szindróma (ARDS), idiopáfiás tíidófibrózís (IPF), gyulladásos bélbetegség pSD|, uveitisz, makutadegeneráció, kői Hisz, pszoriázis, Waller degeneráció, antuföszfolipid szindróma pi*$b akut koronába szindróma, resztenózis, atheroszklerózis, visszaeső poiichondriiis (RP). akut vagy krónikus hepatitisz, sikertelen ortopédiai jmpíantáium, giomeruionefritisz, lupus vagy autoimmun betegségek.
9. Az 1-4. igénypontok bármelyike szerinti humán monekionâlis ellenanyag vagy annak íragmense, vagy az 5. igénypont szerinti poíinukieotld molekula, amely adott esetben tartalmaz még egy vagy több rákellenes szert, egy tumoros betegség, vagy olyan állapot, amely késleltetett sejt apoptózissal, megnőtt sejt túléléssel vagy szaporodással jár, kezelésére szolgáló eljárásban történő alkalmazásra, 1 a A búmén monökSonáiís ellenanyag vagy; annak fragmense, vagy a poiínykíeotiő mole kula 9. igénypont szerinti alkalmazása* ahol a szóban forgó tumoros betegségi ráki, 11A búmén monokionáiis ellenanyag vagy annak fragmense, vagy a poíinukieotld molekula 10, igénypont szerinti alkalmazása, ahol a szóban forgó rák leukémia, többszörös leukémia, gyomor-kémlnóma vagy bőr-karanóma. A meghatalmazott:
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05008410 | 2005-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE025134T2 true HUE025134T2 (hu) | 2016-01-28 |
Family
ID=37115507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE06724392A HUE025134T2 (hu) | 2005-04-18 | 2006-04-18 | A humán granulocita makrofág kolóniastimuláló faktor ellenanyag neutralizálói |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8017748B2 (hu) |
| EP (2) | EP2468774A3 (hu) |
| JP (1) | JP5085533B2 (hu) |
| KR (2) | KR20150091193A (hu) |
| CN (2) | CN101184777B (hu) |
| AU (1) | AU2006237159B2 (hu) |
| BR (1) | BRPI0608281B8 (hu) |
| CA (1) | CA2605402C (hu) |
| CY (1) | CY1116632T1 (hu) |
| DK (1) | DK1874819T3 (hu) |
| EA (2) | EA017420B9 (hu) |
| ES (1) | ES2545769T3 (hu) |
| HK (2) | HK1112003A1 (hu) |
| HR (1) | HRP20150773T1 (hu) |
| HU (1) | HUE025134T2 (hu) |
| IL (2) | IL186486A0 (hu) |
| ME (1) | ME02191B (hu) |
| MX (1) | MX2007012569A (hu) |
| NO (1) | NO344249B1 (hu) |
| NZ (1) | NZ562093A (hu) |
| PL (1) | PL1874819T3 (hu) |
| PT (1) | PT1874819E (hu) |
| RS (1) | RS54127B1 (hu) |
| RU (2) | RU2458071C2 (hu) |
| SG (1) | SG161292A1 (hu) |
| SI (1) | SI1874819T1 (hu) |
| UA (1) | UA94403C2 (hu) |
| WO (1) | WO2006111353A2 (hu) |
| ZA (1) | ZA200708201B (hu) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG161292A1 (en) | 2005-04-18 | 2010-05-27 | Micromet Ag | Antibody neutralizers of human granulocyte macrophage colony stimulating factor |
| JP4736037B2 (ja) * | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| KR101486183B1 (ko) | 2006-02-08 | 2015-01-28 | 모르포테크, 인크. | 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체 |
| US20080171038A1 (en) * | 2006-11-08 | 2008-07-17 | Kalobios Pharmaceuticals, Inc. | Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist |
| US8398972B2 (en) | 2006-11-21 | 2013-03-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a GM-CSF antagonist |
| WO2008097510A1 (en) * | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Antibodies specific for dkk-1 |
| CN101687926A (zh) * | 2007-05-23 | 2010-03-31 | 哮喘和气道Crc有限公司 | 中和抗体 |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| AR069290A1 (es) | 2007-11-13 | 2010-01-13 | Evec Inc | Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden |
| EP3056513A1 (en) * | 2008-04-11 | 2016-08-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| EP3449941A1 (en) * | 2008-04-28 | 2019-03-06 | Humanigen, Inc. | Antibodies to granulocyte-macrophage colony-stimulating factor |
| JP5771140B2 (ja) * | 2008-04-29 | 2015-08-26 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 治療用のｇｍ−ｃｓｆおよびｉｌ−１７阻害剤 |
| US9243061B2 (en) | 2008-12-22 | 2016-01-26 | University Of Melbourne | Osteoarthritis treatment |
| CN102256621B (zh) | 2008-12-22 | 2017-12-12 | 墨尔本大学 | 疼痛治疗 |
| CA2760755A1 (en) * | 2009-05-05 | 2010-11-11 | Morphosys Ag | Treatment for multiple sclerosis |
| MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| CN103827143A (zh) | 2011-07-06 | 2014-05-28 | 莫弗系统股份公司 | 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途 |
| WO2013090989A1 (en) * | 2011-12-22 | 2013-06-27 | Csl Limited | Method of treating inflammatory bowel disease |
| US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| WO2014068029A1 (en) | 2012-10-31 | 2014-05-08 | Takeda Gmbh | Lyophilized formulation comprising gm-csf neutralizing compound |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res (Munich) Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| WO2014138862A1 (en) * | 2013-03-14 | 2014-09-18 | John Schrader | Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof |
| WO2015028666A1 (en) * | 2013-08-30 | 2015-03-05 | Takeda Gmbh | Neutralizing antibody or a fragment thereof specifically binding primate gm-csf for use in the treatment and/or prevention of psoriasis |
| EP3889178A1 (en) * | 2013-08-30 | 2021-10-06 | Takeda GmbH | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics |
| WO2015054691A2 (en) | 2013-10-11 | 2015-04-16 | The United States Of America, As Pepresented By The Secretary, Department Of Health And Human Services | Tem8 antibodies and their use |
| WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| CN106659785B (zh) * | 2014-05-07 | 2021-04-30 | 武田有限公司 | 包含gm-csf中和化合物的液体制剂 |
| WO2016077789A1 (en) | 2014-11-14 | 2016-05-19 | The Usa, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
| WO2016079276A1 (en) * | 2014-11-21 | 2016-05-26 | Takeda Gmbh | Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease |
| WO2016079277A1 (en) * | 2014-11-21 | 2016-05-26 | Takeda Gmbh | Use of an anti-gm-csf antagonist in the treatment of an infectious disease |
| KR20170140180A (ko) | 2015-02-24 | 2017-12-20 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도 |
| GB201503139D0 (en) * | 2015-02-25 | 2015-04-08 | Univ Leicester | Diagnostic and therapeutic target |
| WO2016154003A1 (en) | 2015-03-20 | 2016-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing antibodies to gp120 and their use |
| CA2997809A1 (en) | 2015-10-07 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia |
| GB201519331D0 (en) * | 2015-11-02 | 2015-12-16 | Glaxosmithkline Ip Dev Ltd | Treatment paradigm |
| EP4011911A1 (en) | 2015-11-03 | 2022-06-15 | The United States of America as represented by The Secretary Department of Health and Human Services | Neutralizing antibodies to hiv-1 gp41 and their use |
| WO2017192589A1 (en) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| CN106872428A (zh) * | 2017-02-07 | 2017-06-20 | 远见生物科技（上海）有限公司 | 一种用于检测中性粒细胞呼吸爆发功能的试剂盒 |
| EP3580235B1 (en) | 2017-02-10 | 2024-05-01 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
| US10870703B2 (en) | 2017-10-02 | 2020-12-22 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist |
| US10899831B2 (en) | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
| US10927168B2 (en) | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
| WO2019082869A1 (ja) | 2017-10-24 | 2019-05-02 | アドバンスト・ソフトマテリアルズ株式会社 | 低包接率ポリロタキサンの製造方法 |
| WO2019136029A1 (en) | 2018-01-02 | 2019-07-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
| CA3091437A1 (en) | 2018-02-21 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| US11078264B2 (en) | 2018-10-17 | 2021-08-03 | University Of Connecticut | Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth |
| WO2020132214A2 (en) | 2018-12-20 | 2020-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
| US20220227853A1 (en) | 2019-05-03 | 2022-07-21 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| US20230085439A1 (en) | 2019-05-21 | 2023-03-16 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
| CA3142833A1 (en) | 2019-07-02 | 2021-01-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind egfrviii and their use |
| WO2021204649A1 (en) | 2020-04-06 | 2021-10-14 | Glaxosmithkline Intellectual Property Development Limited | Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome |
| WO2022132904A1 (en) | 2020-12-17 | 2022-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies targeting sars-cov-2 |
| WO2022173670A1 (en) | 2021-02-09 | 2022-08-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies targeting the spike protein of coronaviruses |
| CA3210753A1 (en) | 2021-02-09 | 2022-08-18 | University Of Georgia Research Foundation, Inc. | Human monoclonal antibodies against pneumococcal antigens |
| CA3232223A1 (en) | 2021-09-17 | 2023-03-23 | Ying Fu | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
| WO2023154824A1 (en) | 2022-02-10 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that broadly target coronaviruses |
| WO2023192881A1 (en) | 2022-03-28 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| WO2024030829A1 (en) | 2022-08-01 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
| WO2024054822A1 (en) | 2022-09-07 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered sars-cov-2 antibodies with increased neutralization breadth |
| WO2024064826A1 (en) | 2022-09-22 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8624899D0 (en) | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
| US5070013A (en) * | 1988-05-31 | 1991-12-03 | Schering Corporation | Immunochemical assay for human granulocyte-macrophage colony stimulating factor |
| CA2060741A1 (en) * | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| CA2289691C (en) | 1997-04-23 | 2008-01-15 | Andreas Pluckthun | Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US7112324B1 (en) | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| US7157091B1 (en) * | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
| CN100391469C (zh) | 2000-02-14 | 2008-06-04 | 三菱制药株式会社 | 丙型肝炎治疗药 |
| US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| ES2365606T3 (es) * | 2002-02-13 | 2011-10-07 | Ludwig Institute For Cancer Research Ltd. | Anticuerpos contra gm-csf quiméricos. |
| DE602004021773D1 (de) * | 2004-05-05 | 2009-08-13 | Micromet Ag | Herstellung eines einkettigen fv Antikörperfragments |
| SG161292A1 (en) * | 2005-04-18 | 2010-05-27 | Micromet Ag | Antibody neutralizers of human granulocyte macrophage colony stimulating factor |
| ES2527428T3 (es) | 2005-05-18 | 2015-01-23 | Morphosys Ag | Anticuerpos anti-GM-CSF y usos de los mismos |
| KR101486183B1 (ko) | 2006-02-08 | 2015-01-28 | 모르포테크, 인크. | 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체 |
-
2006
- 2006-04-18 SG SG201002699-5A patent/SG161292A1/en unknown
- 2006-04-18 HU HUE06724392A patent/HUE025134T2/hu unknown
- 2006-04-18 CN CN2006800188584A patent/CN101184777B/zh active Active
- 2006-04-18 RU RU2007138341/10A patent/RU2458071C2/ru active
- 2006-04-18 SI SI200631960T patent/SI1874819T1/sl unknown
- 2006-04-18 AU AU2006237159A patent/AU2006237159B2/en active Active
- 2006-04-18 EP EP12159883A patent/EP2468774A3/en not_active Ceased
- 2006-04-18 NZ NZ562093A patent/NZ562093A/en unknown
- 2006-04-18 BR BRPI0608281A patent/BRPI0608281B8/pt active IP Right Grant
- 2006-04-18 DK DK06724392.3T patent/DK1874819T3/en active
- 2006-04-18 JP JP2008506992A patent/JP5085533B2/ja active Active
- 2006-04-18 ME MEP-2015-111A patent/ME02191B/me unknown
- 2006-04-18 KR KR1020157020152A patent/KR20150091193A/ko active IP Right Grant
- 2006-04-18 PL PL06724392T patent/PL1874819T3/pl unknown
- 2006-04-18 UA UAA200712125A patent/UA94403C2/ru unknown
- 2006-04-18 RS RS20150497A patent/RS54127B1/en unknown
- 2006-04-18 WO PCT/EP2006/003528 patent/WO2006111353A2/en active Application Filing
- 2006-04-18 ES ES06724392.3T patent/ES2545769T3/es active Active
- 2006-04-18 MX MX2007012569A patent/MX2007012569A/es active IP Right Grant
- 2006-04-18 US US11/918,368 patent/US8017748B2/en active Active
- 2006-04-18 CA CA2605402A patent/CA2605402C/en active Active
- 2006-04-18 EA EA200901500A patent/EA017420B9/ru unknown
- 2006-04-18 EP EP06724392.3A patent/EP1874819B1/en active Active
- 2006-04-18 PT PT67243923T patent/PT1874819E/pt unknown
- 2006-04-18 EA EA200702008A patent/EA013162B1/ru unknown
- 2006-04-18 CN CN201310231969.5A patent/CN103342751B/zh active Active
- 2006-04-18 KR KR1020077026929A patent/KR101704809B1/ko active IP Right Grant
-
2007
- 2007-09-20 ZA ZA200708201A patent/ZA200708201B/en unknown
- 2007-10-08 IL IL186486A patent/IL186486A0/en not_active IP Right Cessation
- 2007-11-12 NO NO20075802A patent/NO344249B1/no unknown
-
2008
- 2008-06-17 HK HK08106644.9A patent/HK1112003A1/xx unknown
-
2011
- 2011-08-04 US US13/198,558 patent/US9067993B2/en active Active
-
2012
- 2012-04-20 RU RU2012115683/10A patent/RU2012115683A/ru not_active Application Discontinuation
- 2012-06-14 IL IL220412A patent/IL220412A/en active IP Right Grant
-
2014
- 2014-04-03 HK HK14103216.6A patent/HK1190161A1/zh unknown
-
2015
- 2015-05-21 US US14/718,923 patent/US10138297B2/en active Active
- 2015-07-14 HR HRP20150773TT patent/HRP20150773T1/hr unknown
- 2015-08-20 CY CY20151100731T patent/CY1116632T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10138297B2 (en) | Antibody neutralizers of human granulocyte macrophage colony stimulating factor | |
| CA2562604C (en) | Preparation of scfv antibody fragments | |
| US20130171146A1 (en) | Dual-specific il-1a/ il-1b antibodies | |
| PL181342B1 (pl) | Jednolancuchowe anty-EGFR Fv i przeciwciala anty-EGFR, czasteczka DNA, sposoby wytwarzania jednolancuchowego przeciwciala anty-EGFR i przeciwciala anty-EGFR oraz kompozycja farmaceutyczna PL PL PL PL PL PL PL | |
| CN108473568A (zh) | 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子 | |
| KR20140047170A (ko) | 인간 과립구 마크로파지 콜로니 자극 인자의 중화 항체 | |
| KR20230166120A (ko) | 새로운 tnfr2 결합 분자 |